GlobeNewswire Inc.··Diamond Equity ResearchMAIA Biotech Raises $30M, Eyes 2026 Milestones with Ateganosine Trial Data
MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.
MAIAclinical developmentPhase 3 trial